Twist Bioscience Corp. Hits New 52-Week High of $82.87

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 82.87 on June 15, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2,730 million. Over the past year, Twist Bioscience Corp. has demonstrated impressive growth, with a performance increase of 61.55%, significantly outpacing the S&P 500's 26.39% gain during the same period. Despite being a loss-making company, it continues to attract attention within its industry. Key financial metrics reveal a price-to-book ratio of 5.99, indicating the market's valuation of the company's assets. Additionally, the company has a debt-to-equity ratio of -0.41, reflecting a unique financial structure. However, it is important to note that the company does not offer a dividend yield, and its return on equity stands at -16.79%. The stock's previous 52-week low was recorded at USD 23.50, highlighting the significant upward movement in its price.